Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (28 quarters reported)
$239M in Q4 2015 → — now. Hover for any quarter.
As reported for the quarter ended September 30, 2022. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| NR No Remaining Holdings | NaN% | New | 0 | — |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2022 · filed November 14, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SO Sierra Oncology Inc | Exited | −20,316 | −$1.12M | — |
| NR No Remaining Holdings | New | +0 | — | — |
quarter ended June 30, 2022 · filed August 10, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SO Sierra Oncology Inc | Trimmed | −34,338 | −$1.89M | 100.0% |
| Allena Pharmaceuticals | Exited | −1,019,288 | −$236K | — |
quarter ended March 31, 2022 · filed May 13, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Arcutis Biotherapeutics Inc | Exited | −8,434,232 | −$175M | — |
| Phathom Pharmaceuticals Inc | Exited | −5,827,415 | −$115M | — |
| IB Imago Biosciences Inc | Exited | −2,971,274 | −$70.4M | — |
| Syndax Pharmaceuticals Inc | Exited | −2,772,062 | −$60.7M | — |
| Gritstone Bio Inc | Exited | −4,667,242 | −$60M | — |
| Mirum Pharmaceuticals Inc | Exited | −3,566,912 | −$56.9M | — |
| Vaxcyte Inc | Exited | −2,309,554 | −$54.9M | — |
| Krystal Biotech Inc | Exited | −771,250 | −$53.9M | — |
| PB Pardes Biosciences Inc | Exited | −2,457,507 | −$40.2M | — |
| CP Crinetics Pharmaceuticals In | Exited | −1,384,293 | −$39.3M | — |
Showing the 10 largest of 43 changes.
quarter ended December 31, 2021 · filed February 08, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| TT Trillium Therapeutics Inc | Exited | −3,123,107 | −$55M | — |
| PB Pardes Biosciences Inc | New | +2,457,507 | +$40.2M | 3.1% |
| Syndax Pharmaceuticals Inc | Added | +1,583,927 | +$34.7M | 4.7% |
| Silence Therapeutics PLC | New | +886,173 | +$21.2M | 1.6% |
| Merus N V | New | +559,179 | +$17.8M | 1.4% |
| Iovance Biotherapeutics Inc | Trimmed | −926,677 | −$17.7M | 2.6% |
| T Tricida Inc | New | +1,783,893 | +$17.1M | 1.3% |
| Cogent Biosciences Inc | New | +1,774,891 | +$15.2M | 1.2% |
| Kalvista Pharmaceuticals Inc | Added | +1,148,280 | +$15.2M | 1.3% |
| CP Crinetics Pharmaceuticals In | Added | +532,987 | +$15.1M | 3.0% |
Showing the 10 largest of 24 changes.
quarter ended September 30, 2021 · filed November 12, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| IB Imago Biosciences Inc | New | +2,971,274 | +$59.5M | 4.8% |
| Translate Bio Inc | Exited | −2,082,789 | −$57.4M | — |
| Gritstone Bio Inc | Added | +3,636,364 | +$39.3M | 4.0% |
| Viridian Therapeutics Inc | New | +1,505,200 | +$24.8M | 2.0% |
| Tyra Biosciences Inc | New | +1,250,000 | +$22M | 1.8% |
| Bicycle Therapeutics PLC | New | +442,880 | +$18.4M | 1.5% |
| CP Crinetics Pharmaceuticals In | New | +851,306 | +$17.9M | 1.4% |
| Replimune Group Inc | New | +491,998 | +$14.6M | 1.2% |
| Iovance Biotherapeutics Inc | Added | +536,300 | +$13.2M | 5.3% |
| SO Sierra Oncology Inc | Added | +601,864 | +$13.2M | 1.4% |
Showing the 10 largest of 24 changes.
quarter ended June 30, 2021 · filed August 11, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Arcutis Biotherapeutics Inc | Trimmed | −2,108,558 | −$57.5M | 21.2% |
| Iovance Biotherapeutics Inc | Added | +825,000 | +$21.5M | 5.1% |
| CT Chinook Therapeutics Inc | New | +1,100,000 | +$15.5M | 1.4% |
| Autolus Therapeutics PLC | New | +2,283,966 | +$15.2M | 1.4% |
| Tarsus Pharmaceuticals Inc | Trimmed | −500,000 | −$14.5M | 3.8% |
| Adverum Biotechnologies Inc | Exited | −1,437,028 | −$14.2M | — |
| Krystal Biotech Inc | Trimmed | −107,124 | −$7.28M | 4.9% |
| Aclaris Therapeutics Inc | Trimmed | −325,267 | −$5.71M | 0.6% |
| Syndax Pharmaceuticals Inc | Trimmed | −246,910 | −$4.24M | 1.9% |
| Aptinyx Inc | Trimmed | −1,306,835 | −$3.7M | 0.5% |
Showing the 10 largest of 14 changes.
quarter ended March 31, 2021 · filed May 12, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Collegium Pharmaceutical Inc | Exited | −943,666 | −$18.9M | — |
| Aclaris Therapeutics Inc | New | +696,000 | +$17.5M | 1.4% |
| GO Gritstone Oncology Inc | Trimmed | −1,030,880 | −$9.72M | 0.8% |
| Rocket Pharmaceuticals Inc | Exited | −168,000 | −$9.21M | — |
| Essa Pharma Inc | New | +316,616 | +$9.2M | 0.7% |
| Immunovant Inc | New | +508,000 | +$8.15M | 0.7% |
| MT Molecular Templates Inc | Added | +532,139 | +$6.72M | 1.4% |
| Avadel Pharmaceuticals PLC | New | +578,104 | +$5.23M | 0.4% |
| Cardiff Oncology Inc | Trimmed | −275,000 | −$2.55M | 0.2% |
| ST Silverback Therapeutics Inc | Exited | −35,750 | −$1.66M | — |
Showing the 10 largest of 17 changes.
quarter ended December 31, 2020 · filed February 11, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Tarsus Pharmaceuticals Inc | New | +1,917,157 | +$79.2M | 6.1% |
| Anaptysbio Inc | Trimmed | −1,416,747 | −$30.5M | 1.5% |
| Sutro Biopharma Inc | New | +1,001,421 | +$21.7M | 1.7% |
| Rocket Pharmaceuticals Inc | Trimmed | −360,000 | −$19.7M | 0.7% |
| FL Frazier Lifesciences Acqu Co | New | +1,501,000 | +$15.6M | 1.2% |
| E Epizyme Inc | New | +731,436 | +$7.94M | 0.6% |
| MT Molecular Templates Inc | New | +841,908 | +$7.91M | 0.6% |
| Regenxbio Inc | Added | +167,754 | +$7.61M | 1.2% |
| SR Scholar Rock Hldg Corp | New | +153,500 | +$7.45M | 0.6% |
| Cardiff Oncology Inc | Added | +308,500 | +$5.55M | 0.8% |
Showing the 10 largest of 22 changes.
Loading...
